



# SZABO SCANDIC

Part of Europa Biosite

## Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!  
See the following pages for more information!



### Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

### Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

### SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7


[mail@szabo-scandic.com](mailto:mail@szabo-scandic.com)

[www.szabo-scandic.com](http://www.szabo-scandic.com)

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

## XL413

|                           |   |       |          |
|---------------------------|---|-------|----------|
| <b>Cat. No.:</b>          | HY-15260  |       |          |
| <b>CAS No.:</b>           | 1169558-38-6  |       |          |
| <b>Molecular Formula:</b> | C <sub>14</sub> H <sub>12</sub> ClN <sub>3</sub> O <sub>2</sub> |       |          |
| <b>Molecular Weight:</b>  | 289.72  |       |          |
| <b>Target:</b>            | CDK   |       |          |
| <b>Pathway:</b>           | Cell Cycle/DNA Damage   |       |          |
| <b>Storage:</b>           | Powder  | -20°C | 3 years  |
|                           |   | 4°C   | 2 years  |
|                           | In solvent  | -80°C | 6 months |
|                           |   | -20°C | 1 month  |



### SOLVENT & SOLUBILITY

|   |   |                          |              |            |            |
|---|---|--------------------------|--------------|------------|------------|
| <b>In Vitro</b>   | DMSO : 3.45 mg/mL (11.91 mM; ultrasonic and warming and heat to 60°C)   |                          |              |            |            |
|   |   | Solvent<br>Concentration | Mass<br>1 mg | 5 mg       | 10 mg      |
|   | <b>Preparing Stock Solutions</b>  | 1 mM                     | 3.4516 mL    | 17.2580 mL | 34.5161 mL |
|   |   | 5 mM                     | 0.6903 mL    | 3.4516 mL  | 6.9032 mL  |
| 10 mM   |   | 0.3452 mL                | 1.7258 mL    | 3.4516 mL  |            |
| Please refer to the solubility information to select the appropriate solvent. |   |                          |              |            |            |
| <b>In Vivo</b>  | <ol style="list-style-type: none"> <li>Add each solvent one by one: 10% DMSO &gt;&gt; 90% (20% SBE-β-CD in saline)<br/>Solubility: ≥ 0.35 mg/mL (1.21 mM); Clear solution</li> <li>Add each solvent one by one: 10% DMSO &gt;&gt; 90% corn oil<br/>Solubility: ≥ 0.35 mg/mL (1.21 mM); Clear solution</li> <li>Add each solvent one by one: 10% DMSO &gt;&gt; 40% PEG300 &gt;&gt; 5% Tween-80 &gt;&gt; 45% saline<br/>Solubility: ≥ 0.34 mg/mL (1.17 mM); Clear solution</li> </ol> |                          |              |            |            |

### BIOLOGICAL ACTIVITY

|                                     |   |                                   |                                   |
|-------------------------------------|---|-----------------------------------|-----------------------------------|
| <b>Description</b>                  | XL413 is a potent, selective and ATP competitive inhibitor of Cdc7, with an IC <sub>50</sub> of 3.4 nM, and also shows potent effect with IC <sub>50</sub> s of 215, 42 nM on CK2, PIM1, respectively, and an EC <sub>50</sub> of 118 nM on pMCM. |                                   |                                   |
| <b>IC<sub>50</sub> &amp; Target</b> | Cdc7<br>3.4 nM (IC <sub>50</sub> )  | PIM1<br>42 nM (IC <sub>50</sub> ) | CK2<br>215 nM (IC <sub>50</sub> ) |
| <b>In Vitro</b>                     | XL413 inhibits the cell proliferation (IC <sub>50</sub> = 2685 nM), decreases cell viability (IC <sub>50</sub> = 2142 nM) and elicits the caspase 3/7   |                                   |                                   |

activity ( $EC_{50} = 2288$  nM) in Colo-205 cells. XL413 also significantly inhibits the anchorage-independent growth of colo-205 in soft agar ( $IC_{50} = 715$  nM)<sup>[1]</sup>. XL413 shows cytotoxic effects on tumors, with  $IC_{50}$  of 22.9  $\mu$ M in HCC1954 cells and 1.1  $\mu$ M in Colo-205 cells. XL413 induces apoptosis in the Colo-205 cells, but not in HCC1954 cells. XL413 is effective DDK inhibitors in vitro, with  $IC_{50}$  of 22.7 nM. XL413 is defective in inhibiting DDK-dependent Mcm2 phosphorylation in HCC1954 cells but is effective in Colo-205 cells<sup>[2]</sup>.

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

#### In Vivo

XL413 (100 mg/kg, p.o.) shows excellent plasma exposures in mice and possesses good PK properties. XL413 (10, 30, or 100 mg/kg, p.o.) is well tolerated at all the doses, with no significant body weight loss<sup>[1]</sup>.

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

## PROTOCOL

#### Kinase Assay <sup>[2]</sup>

20 ng of purified human DDK is pre-incubated with increasing concentrations of each DDK inhibitor for 5 min. Then 10  $\mu$ Ci ( $\gamma$ )-<sup>32</sup>P ATP and 1.5  $\mu$ M cold ATP are added in a buffer containing 50 mM Tris-HCl (pH 7.5), 10 mM MgCl<sub>2</sub>, and 1 mM DTT and incubated for 30 min at 30°C. The proteins are denatured in 1X Laemmli buffer at 100°C followed by SDS-PAGE and autoradiography on HyBlot CL film. Auto-phosphorylation of DDK is used as an indicator of its kinase activity. <sup>32</sup>P-labeled bands are quantified using ImageJ and the  $IC_{50}$  values are calculated using GraphPad.

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

#### Cell Assay <sup>[2]</sup>

For assays in 96 well plates 2500 cells are plated per well. After 24 hours, cells are treated with small molecule inhibitors and incubated for 72 hours at 37°C. Subsequently the cells are lysed and the ATP content is measured as an indicator of metabolically active cells using the CellTiter-Glo assay.  $IC_{50}$  values are calculated using the GraphPad software. For assays in six well plates, 100,000 cells are plated per well. After 24 hours, cells are treated with small molecule inhibitors and incubated for varying time points. Cells are trypsinized and a suspension is made in 5 mL of phosphate buffered saline. 30  $\mu$ L of this suspension is mixed with 30  $\mu$ L of CellTiter-Glo reagent followed by a 10-minute incubation at room temperature. Luminescence is measured using EnVision 2104 Multilabel Reader and BioTek Synergy Neo Microplate Reader.

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

## CUSTOMER VALIDATION

- Science. 2017 Dec 1;358(6367):eaan4368.
- Sens Actuators B Chem. 15 May 2022, 131618.
- Am J Physiol Lung Cell Mol Physiol. 2018 Sep 1;315(3):L360-L370.
- Harvard Medical School LINCS LIBRARY

See more customer validations on [www.MedChemExpress.com](http://www.MedChemExpress.com)

## REFERENCES

[1]. Koltun ES, et al. Discovery of XL413, a potent and selective CDC7 inhibitor. *Bioorg Med Chem Lett*. 2012 Jun 1;22(11):3727-31.

[2]. Sasi NK, et al. The potent Cdc7-Dbf4 (DDK) kinase inhibitor XL413 has limited activity in many cancer cell lines and discovery of potential new DDK inhibitor scaffolds. *PLoS One*. 2014 Nov 20;9(11):e113300.

---

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA